Prediction of preeclampsia: Can it be achieved?

Obstetrical and Gynecological Survey

Volumn 59, Issue 6, 2004, Pages 464-482

  Farag, Khalid ^a   Hassan, Ismail ^b   Ledger, William L ^c,d  

^a BARNSLEY DISTRICT GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^c JESSOP HOSPITAL FOR WOMEN   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; CREATININE; KALLIKREIN;

BLOOD PRESSURE; FIRST TRIMESTER PREGNANCY; HIGH RISK POPULATION; HUMAN; HYPOCALCIURIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; ISCHEMIA; MASS SCREENING; MICROALBUMINURIA; PLACENTA DISORDER; PLACENTA ISCHEMIA; PREDICTION; PREECLAMPSIA; REVIEW; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; URINALYSIS;

BIOLOGICAL MARKERS; FEMALE; HUMANS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 2542468117     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-200406000-00025     Document Type: Review

References (215)

1. Sibai BM, Ewell M, Levine RJ, et al. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol 1997;177:1003-1010.
2. Department of Health. WHY MOTHERS DIE Report for 1997-1999. Confidential Enquiry Into Maternal Deaths in the United Kingdom. London: Stationery Office, 2001.
3. Roberts JM, Taylor RN, Musci TJ, et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;161:1200-1204.
4. Sibai BM. Prevention of preeclampsia: a big disappointment. Am J Obstet Gynecol 1998;179:1275-1278.
5. Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991;165:1408-1412.
6. Redman CW. Immunology of preeclampsia. Semin Perinatol 1991;15:257-262.
7. Roberts JM, Cooper DW. Pathogenesis and genetics of preeclampsia. Lancet 2001;357:53-56.
8. Smarason AK, Sargent IL, Starkey PM, et al. The effect of placental syncytiotrophoblast microvillous membranes from normal and pre-eclamptic women on the growth of endothelial cells in vitro. Br J Obstet Gynaecol 1993;100:943-949.
9. Arbogast BW, Leeper SC, Merrick RD, et al. Which plasma factors bring about disturbance of endothelial function in pre-eclampsia? Lancet 1994;343:340-341.
10. Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996;175:1365-1370.
11. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180:499-506.
12. Chesley LC, Cooper DW. Genetics of hypertension in pregnancy: possible single gene control of pre-eclampsia and eclampsia in the descendants of eclamptic women. Br J Obstet Gynaecol 1986;93:898-908.
13. Kaaja R, Julkunen H, Ammala P. Hypertension as a risk factor in pregnancies complicated by systemic lupus erythematosus. Acta Obstet Gynecol Scand 1990;69:393-396.
14. Marcoux S, Berube S, Brisson J, et al. History of migraine and risk of pregnancy-induced hypertension. Epidemiology 1992;3:53-56.
15. Suhonen L, Teramo K. Hypertension and pre-eclampsia in women with gestational glucose intolerance. Acta Obstet Gynecol Scand 1993;72:269-272.
16. Millar LK, Wing DA, Leung AS, et al. Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstet Gynecol 1994;84:946-949.
17. Rey E, Couturier A. The prognosis of pregnancy in women with chronic hypertension. Am J Obstet Gynecol 1994;171:410-416.
18. Mittendorf R, Lain KY, Williams MA, et al. Preeclampsia. A nested, case-control study of risk factors and their interactions. J Reprod Med 1996;41:491-496.
19. de Vries MJ, Dekker GA, Schoemaker J. Higher risk of preeclampsia in the polycystic ovary syndrome. A case control study. Eur J Obstet Gynecol Reprod Biol 1998;76:91-95.
20. Fink JC, Schwartz SM, Benedetti TJ, et al. Increased risk of adverse maternal and infant outcomes among women with renal disease. Paediatr Perinat Epidemiol 1998;12:277-287.
21. Ros HS, Cnattingius S, Lipworth L. Comparison of risk factors for preeclampsia and gestational hypertension in a population-based cohort study. Am J Epidemiol 1998;147:1062-1070.
22. Innes KE, Marshall JA, Byers TE, et al. A woman's own birth weight and gestational age predict her later risk of developing preeclampsia, a precursor of chronic disease. Epidemiology 1999;10:153-160.
23. Moutquin JM, Rainville C, Giroux L, et al. A prospective study of blood pressure in pregnancy: prediction of preeclampsia. Am J Obstet Gynecol 1985;151:191-196.
24. Page EW, Christianson R. The impact of mean arterial pressure in the middle trimester upon the outcome of pregnancy. Am J Obstet Gynecol 1976;125:740-746.
25. Caritis S, Sibai B, Hauth J, et al. Predictors of pre-eclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 1998;179:946-951.
26. Higgins JR, Walshe JJ, Halligan A, et al. Can 24-hour ambulatory blood pressure measurement predict the development of hypertension in primigravidae? Br J Obstet Gynaecol 1997;104:356-362.
27. Talledo OE. Renin-angiotensin system in normal and toxemic pregnancies. I. Angiotensin infusion test. Am J Obstet Gynecol 1966;96:141-143.
28. Conde-Agudelo A, Lede R, Belizan J. Evaluation of methods used in the prediction of hypertensive disorders of pregnancy. Obstet Gynecol Surv 1994;49:210-222.
29. Kyle PM, Buckley D, Kissane J, et al. The angiotensin sensitivity test and low-dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. Am J Obstet Gynecol 1995;173:865-872.
30. Cole LA, Kardana A, Andrade-Gordon P, et al. The heterogeneity of human chorionic gonadotropin (hCG). III. The occurrence and biological and immunological activities of nicked hCG. Endocrinology 1991;129:1559-1567.
31. Cole LA, Kardana A, Park SY, et al. The deactivation of hCG by nicking and dissociation. J Clin Endocrinol Metab 1993;76:704-710.
32. Bahado-Singh RO, Oz U, Isozaki T, et al. Midtrimester urine human chorionic gonadotropin beta-subunit core fragment levels and the subsequent development of pre-eclampsia. Am J Obstet Gynecol 1998;179:738-741.
33. Tolaymat A, Sanchez-Ramos L, Yergey AL, et al. Pathophysiology of hypocalciuria in preeclampsia: measurement of intestinal calcium absorption. Obstet Gynecol 1994;83:239-243.
34. Suarez VR, Trelles JG, Miyahira JM. Urinary calcium in asymptomatic primigravidas who later developed preeclampsia. Obstet Gynecol 1996;87:79-82.
35. Taufield PA, Ales KL, Resnick LM, et al. Hypocalciuria in preeclampsia. N Engl J Med 1987;316:715-718.
36. Sanchez-Ramos L, Jones DC, Cullen MT. Urinary calcium as an early marker for preeclampsia. Obstet Gynecol 1991;77:685-688.
37. Baker PN, Hackett GA. The use of urinary albumin-creatinine ratios and calcium-creatinine ratios as screening tests for pregnancy-induced hypertension. Obstet Gynecol 1994;83:745-749.
38. Saudan PJ, Shaw L, Brown MA. Urinary calcium/creatinine ratio as a predictor of preeclampsia. Am J Hypertens 1998;11:839-843.
39. Millar JG, Campbell SK, Albano JD, et al. Early prediction of pre-eclampsia by measurement of kallikrein and creatinine on a random urine sample. Br J Obstet Gynaecol 1996;103:421-426.
40. Kyle PM, Campbell S, Buckley D, et al. A comparison of the inactive urinary kallikrein:creatinine ratio and the angiotensin sensitivity test for the prediction of pre-eclampsia. Br J Obstet Gynaecol 1996;103:981-987.
41. Eden RD, Wahbeh CJ, Williams AY, et al. Nephelometric urinary protein profile as an index of renal involvement in hypertensive disorders of pregnancy. Am J Obstet Gynecol 1983;147:645-651.
42. Irgens-Moller L, Hemmingsen L, Holm J. Diagnostic value of micmalbuminuria in pre-eclampsia. Clin Chim Acta 1986;157:295-298.
43. Konstantin-Hansen KF, Hesseldahl H, Pedersen SM. Microalbuminuria as a predictor of preeclampsia. Acta Obstet Gynecol Scand 1992;71:343-346.
44. Rodriguez MH, Masaki DI, Mestman J, et al. Calcium/creatinine ratio and micmalbuminuria in the prediction of preeclampsia. Am J Obstet Gynecol 1988;159:1452-1455.
45. Das V, Bhargava T, Das SK, et al. Microalbuminuria: a predictor of pregnancy-induced hypertension. Br J Obstet Gynaecol 1996;103:928-930.
46. Bar J, Hod M, Erman A, et al. Micmalbuminuria as an early predictor of hypertensive complications in pregnant women at high risk. Am J Kidney Dis 1996;28:220-225.
47. Shaarawy M, Salem ME. The clinical value of microtransferrinuria and microalbuminuria in the prediction of preeclampsia. Clin Chem Lab Med 2001;39:29-34.
48. Petraglia F, De Vita D, Gallinelli A, et al. Abnormal concentration of maternal serum activin-A in gestational diseases. J Clin Endocrinol Metab 1995;80:558-561.
49. Fraser RF, McAsey ME, Coney P. Inhibin-A and pro-alpha C are elevated in preeclamptic pregnancy and correlate with human chorionic gonadotropin. Am J Reprod Immunol 1998;40:37-42.
50. Laivuori H, Kaaja R, Turpeinen U, et al. Serum activin A and inhibin A elevated in pre-eclampsia: no relation to insulin sensitivity. Br J Obstet Gynaecol 1999;106:1298-1303.
51. D'Antona D, Reis FM, Benedetto C, et al. Increased maternal serum activin A but not follistatin levels in pregnant women with hypertensive disorders. J Endocrinol 2000;165:157-162.
52. Silver HM, Lambert-Messerlian GM, Star JA, et al. Comparison of maternal serum total activin A and inhibin A in normal, preeclamptic, and nonproteinuric gestationally hypertensive pregnancies. Am J Obstet Gynecol 1999;180:1131-1137.
53. Muttukrishna S, Knight PG, Groome NP, et al. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet 1997;349:1285-1288.
54. Aquilina J, Barnett A, Thompson O, et al. Second-trimester maternal serum inhibin A concentration as an early marker for preeclampsia. Am J Obstet Gynecol 1999;181:131-136.
55. Cuckle H, Sehmi I, Jones R. Maternal serum inhibin A can predict pre-eclampsia. Br J Obstet Gynaecol 1998;105:1101-1103.
56. Grobman WA, Wang EY. Serum levels of activin A and inhibin A and the subsequent development of preeclampsia. Obstet Gynecol 2000;96:390-394.
57. Raty R, Koskinen P, Alanen A, et al. Prediction of preeclampsia with maternal mid-trimester total renin, inhibin A, AFP and free beta-hCG levels. Prenat Diagn 1999;19:122-127.
58. Muttukrishna S, North RA, Morris J, et al. Serum inhibin A and activin A are elevated prior to the onset of preeclampsia. Hum Reprod 2000;15:1640-1645.
59. Gordon YB, Grudzinskas JG, Kitau MJ, et al. Fetal wastage as a result of an alpha-fetoprotein screening programme. Lancet 1978;1:677-678.
60. Hamilton MP, Abdalla HI, Whitfield CR. Significance of raised maternal serum alpha-fetoprotein in singleton pregnancies with normally formed fetuses. Obstet Gynecol 1985;65:465-470.
61. Walters BN, Lao T, Smith V, et al. alpha-Fetoprotein elevation and proteinuric pre-eclampsia. Br J Obstet Gynaecol 1985;92:341-344.
62. Milunsky A, Jick SS, Bruell CL, et al. Predictive values, relative risks, and overall benefits of high and low maternal serum alpha-fetoprotein screening in singleton pregnancies: new epidemiologic data. Am J Obstet Gynecol 1989;161:291-297.
63. Williams MA, Hickok DE, Zingheim RW, et al. Elevated maternal serum alpha-fetoprotein levels and midtrimester placental abnormalities in relation to subsequent adverse pregnancy outcomes. Am J Obstet Gynecol 1992;167:1032-1037.
64. Brazerol WF, Grover S, Donnenfeld AE. Unexplained elevated maternal serum alpha-fetoprotein levels and perinatal outcome in an urban clinic population. Am J Obstet Gynecol 1994;171:1030-1035.
65. Lo YM, Leung TN, Tein MS, et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem 1999;45:184-188.
66. Al Mufti R, Hambley H, Albaiges G, et al. Increased fetal erythroblasts in women who subsequently develop preeclampsia. Hum Reprod 2000;15:1624-1628.
67. Leung TN, Chung TK, Madsen G, et al. Analysis of midtrimester corticotrophin-releasing hormone and alpha-fetoprotein concentrations for predicting pre-eclampsia. Hum Reprod 2000;15:1813-1818.
68. Smith GV, Smith OW. Anterior pituitary like hormone in late pregnancy toxemia: summary of results since 1932. Am J Obstet Gynecol 1939;36:618-624.
69. Crosignani PG, Trojsi L, Attanasio AE, et al. Value of HCG and HCS measurement in clinical practice. Obstet Gynecol 1974;44:673-681.
70. Fox H. Effect of hypoxia on trophoblast in organ culture. A morphologic and autoradiographic study. Am J Obstet Gynecol 1970;107:1058-1064.
71. Vaillant P, David E, Lemay C, et al. [Plasma beta chorionic gonadotropin between 14 and 20 weeks of amenorrhea: a sign of pregnancy-related hypertension.] Presse Med 1992;21:1413-1418.
72. Gravett CP, Buckmaster JG, Watson PT, et al. Elevated second trimester maternal serum beta-HCG concentrations and subsequent adverse pregnancy outcome. Am J Med Genet 1992;44:485-486.
73. Muller F, Savey L, Le Fiblec B, et al. Maternal serum human chorionic gonadotropin level at fifteen weeks is a predictor for preeclampsia. Am J Obstet Gynecol 1996;175:37-40.
74. Sorensen TK, Williams MA, Zingheim RW, et al. Elevated second-trimester human chorionic gonadotropin and subsequent pregnancy-induced hypertension. Am J Obstet Gynecol 1993;169:834-838.
75. Livingston JC, Haddad B, Gorski LA, et al. Placenta growth factor is not an early marker for the development of severe preeclampsia. Am J Obstet Gynecol 2001;184:1218-1220.
76. Ong CY, Liao AW, Cacho AM, et al. First-trimester maternal serum levels of placenta growth factor as predictor of preeclampsia and fetal growth restriction. Obstet Gynecol 2001;98:608-611.
77. Tjoa ML, van Vugt JM, Mulders MA, et al. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001;98:600-607.
78. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374-381.
79. Bonora E, Willeit J, Kiechl S, et al. U-shaped and J-shaped relationships between serum insulin and coronary heart disease in the general population. The Bruneck Study. Diabetes Care 1998;21:221-230.
80. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991;34:457-462.
81. Steinberg HO, Chaker H, Learning R, et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996;97:2601-2610.
82. McCarty MF. Hemostatic concomitants of syndrome X. Med Hypotheses 1995;44:179-193.
83. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care 1999;22(suppl 3):C25-C30.
84. Solomon CG, Seely EW. Brief review: hypertension in pregnancy: a manifestation of the insulin resistance syndrome? Hypertension 2001;37:232-239.
85. Smith U, Axelsen M, Carvalho E, et al. Insulin signaling and action in fat cells: associations with insulin resistance and type 2 diabetes. Ann N Y Acad Sci 1999;892:119-126.
86. Chen HL, Yang YP, Hu XL, et al. Tumor necrosis factor alpha mRNA and protein are present in human placental and uterine cells at early and late stages of gestation. Am J Pathol 1991;139:327-335.
87. Masuzaki H, Ogawa Y, Sagawa N, et al. Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. Nat Med 1997;3:1029-1033.
88. Lepercq J, Challier JC, Guerre-Millo M, et al. Prenatal leptin production: evidence that fetal adipose tissue produces leptin. J Clin Endocrinol Metab 2001;86:2409-2413.
89. Kirwan JP, Hauguel-de Mouzon S, Lepercq J, et al. TNF-alpha is a predictor of insulin resistance in human pregnancy. Diabetes 2002;51:2207-2213.
90. Lindsay MK, Graves W, Klein L. The relationship of one abnormal glucose tolerance test value and pregnancy complications. Obstet Gynecol 1989;73:103-106.
91. Solomon CG, Graves SW, Greene MF, et al. Glucose intolerance as a predictor of hypertension in pregnancy. Hypertension 1994;23:717-721.
92. Sermer M, Naylor CD, Gare DJ, et al. Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in 3637 women without gestational diabetes. The Toronto Tri-Hospital Gestational Diabetes Project. Am J Obstet Gynecol 1995;173:146-156.
93. Sowers JR, Saleh AA, Sokol RJ. Hyperinsulinemia and insulin resistance are associated with preeclampsia in African-Americans. Am J Hypertens 1995;8:1-4.
94. Joffe GM, Esterlitz JR, Levine RJ, et al. The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol 1998;179:1032-1037.
95. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-546.
96. Mise H, Sagawa N, Matsumoto T, et al. Augmented placental production of leptin in preeclampsia: possible involvement of placental hypoxia. J Clin Endocrinol Metab 1998;83:3225-3229.
97. McCarthy JF, Misra DN, Roberts JM. Maternal plasma leptin is increased in preeclampsia and positively correlates with fetal cord concentration. Am J Obstet Gynecol 1999;180:731-736.
98. Highman TJ, Friedman JE, Huston LP, et al. Longitudinal changes in maternal serum leptin concentrations, body composition, and resting metabolic rate in pregnancy. Am J Obstet Gynecol 1998;178:1010-1015.
99. Anim-Nyame N, Sooranna SR, Steer PJ, et al. Longitudinal analysis of maternal plasma leptin concentrations during normal pregnancy and pre-eclampsia. Hum Reprod 2000;15:2033-2036.
100. Martinez-Abundis E, Gonzalez-Ortiz M, Pascoe-Gonzalez S. Serum leptin levels and the severity of preeclampsia. Arch Gynecol Obstet 2000;264:71-73.
101. Byrne CD. Does tumour necrosis factor alpha influence insulin sensitivity in skeletal muscle? Clin Sci (Lond) 2000;99:329-330.
102. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001;22:36-52.
103. Guilbert L, Robertson SA, Wegmann TG. The trophoblast as an integral component of a macrophage-cytokine network. Immunol Cell Biol 1993;71 (part 1):49-57.
104. Benyo DF, Miles TM, Conrad KP. Hypoxia stimulates cytokine production by villous explants from the human placenta. J Clin Endocrinol Metab 1997;82:1582-1588.
105. Williams MA, Farrand A, Mittendorf R, et al. Maternal second trimester serum tumor necrosis factor-alpha-soluble receptor p55 (sTNFp55) and subsequent risk of preeclampsia. Am J Epidemiol 1999;149:323-329.
106. Estelles A, Gilabert J, Grancha S, et al. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia. Thromb Haemost 1998;79:500-508.
107. Fisher KA, Luger A, Spargo BH, et al. Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine (Baltimore) 1981;60:267-276.
108. Kupferminc MJ, Peaceman AM, Wigton TR, et al. Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am J Obstet Gynecol 1994;170:1752-1757.
109. Vince GS, Starkey PM, Austgulen R, et al. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 1995;102:20-25.
110. Wang Y, Walsh SW. TNF alpha concentrations and mRNA expression are increased in preeclamptic placentas. J Reprod Immunol 1996;32:157-169.
111. Rinehart BK, Terrone DA, Lagoo-Deenadayalan S, et al. Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia. Am J Obstet Gynecol 1999;181:915-920.
112. Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol 1997;37:240-249.
113. Livingston JC, Park V, Barton JR, et al. Lack of association of severe preeclampsia with maternal and fetal mutant alleles for tumor necrosis factor alpha and lymphotoxin alpha genes and plasma tumor necrosis factor alpha levels. Am J Obstet Gynecol 2001;184:1273-1277.
114. Anderson DC. Sex-hormone-binding globulin. Clin Endocrinol (Oxf) 1974;3:69-96.
115. Plymate SR, Matej LA, Jones RE, et al. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988;67:460-464.
116. O'Leary P, Boyne P, Flett P, et al. Longitudinal assessment of changes in reproductive hormones during normal pregnancy. Clin Chem 1991;37:667-672.
117. Key TJ, Pike MC, Moore JW, et al. The relationship of free fatty acids with the binding of oestradiol to SHBG and to albumin in women. J Steroid Biochem 1990;35:35-38.
118. Wolf M, Sandler L, Jimenez-Kimble R, et al. Insulin resistance but not inflammation is associated with gestational hypertension. Hypertension 2002;40:886-891.
119. Wolf M, Sandler L, Munoz K, et al. First trimester insulin resistance and subsequent preeclampsia: a prospective study. J Clin Endocrinol Metab 2002;87:1563-1568.
120. Vartio T, Laitinen L, Narvanen O, et al. Differential expression of the ED sequence-containing form of cellular fibronectin in embryonic and adult human tissues. J Cell Sci 1987;88(part 4):419-430.
121. Peters JH, Maunder RJ, Woolf AD, et al. Elevated plasma levels of ED1 + ('cellular') fibronectin in patients with vascular injury. J Lab Clin Med 1989;113:586-597.
122. Ulrich MM, Janssen AM, Daemen MJ, et al. Increased expression of fibronectin isoforms after myocardial infarction in rats. J Mol Cell Cardiol 1997;29:2533-2543.
123. Peters JH, Ginsberg MH, Bohl BP, et al. Intravascular release of intact cellular fibronectin during oxidant-induced injury of the in vitro perfused rabbit lung. J Clin Invest 1986;78:1596-1603.
124. Peters JH, Ginsberg MH, Case CM, et al. Release of soluble fibronectin containing an extra type III domain (ED1) during acute pulmonary injury mediated by oxidants or leukocytes in vivo. Am Rev Respir Dis 1988;138:167-174.
125. Dreyfus M, Baldauf JJ, Ritter J, et al. The prediction of preeclampsia: reassessment of clinical value of increased plasma levels of fibronectin. Eur J Obstet Gynecol Reprod Biol 1998;78:25-28.
126. Gredmark T, Bergman B, Hellstrom L. Total fibronectin in maternal plasma as a predictor for preeclampsia. Gynecol Obstet Invest 1999;47:89-94.
127. Sud SS, Gupta I, Dhaliwal LK, et al. Serial plasma fibronectin levels in pre-eclamptic and normotensive women. Int J Gynaecol Obstet 1999;66:123-128.
128. Chavarria ME, Lara-Gonzalez L, Gonzalez-Gleason A, et al. Maternal plasma cellular fibronectin concentrations in normal and preeclamptic pregnancies: a longitudinal study for early prediction of preeclampsia. Am J Obstet Gynecol 2002;187:595-601.
129. Islami D, Shoukir Y, Dupont P, et al. Is cellular fibronectin a biological marker for pre-eclampsia? Eur J Obstet Gynecol Reprod Biol 2001;97:40-45.
130. Majzoub JA, McGregor JA, Lockwood CJ, et al. A central theory of preterm and term labor: putative role for corticotropin-releasing hormone. Am J Obstet Gynecol 1999;180: S232-S241.
131. Wolfe CD, Patel SP, Linton EA, et al. Plasma corticotrophin-releasing factor (CRF) in abnormal pregnancy. Br J Obstet Gynaecol 1988;95:1003-1006.
132. Emanuel RL, Robinson BG, Seely EW, et al. Corticotrophin releasing hormone levels in human plasma and amniotic fluid during gestation. Clin Endocrinol (Oxf) 1994;40:257-262.
133. Laatikainen T, Virtanen T, Kaaja R, et al. Corticotropin-releasing hormone in maternal and cord plasma in preeclampsia. Eur J Obstet Gynecol Reprod Biol 1991;39:19-24.
134. Perkins AV, Linton EA, Eben F, et al. Corticotrophin-releasing hormone and corticotrophin-releasing hormone binding protein in normal and pre-eclamptic human pregnancies. Br J Obstet Gynaecol 1995;102:118-122.
135. Kanani PM, Sinkey CA, Browning RL, et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999;100:1161-1168.
136. Upchurch GR Jr, Welch GN, Loscalzo J. Homocysteine, EDRF, and endothelial function. J Nutr 1996;126:1290S-1294S.
137. Powers RW, Evans RW, Ness RB, et al. Homocysteine and cellular fibronectin are increased in preeclampsia, not transient hypertension of pregnancy. Hypertens Pregnancy 2001;20:69-77.
138. Cotter AM, Molloy AM, Scott JM, et al. Elevated plasma homocysteine in early pregnancy: a risk factor for the development of severe preeclampsia. Am J Obstet Gynecol 2001;185:781-785.
139. Hietala R, Turpeinen U, Laatikainen T. Serum homocysteine at 16 weeks and subsequent preeclampsia. Obstet Gynecol 2001;97:527-529.
140. Lachmeijer AM, Arngrimsson R, Bastiaans EJ, et al. Mutations in the gene for methylenetetrahydrofolate reductase, homocysteine levels, and vitamin status in women with a history of preeclampsia. Am J Obstet Gynecol 2001;184:394-402.
141. Page NM, Woods RJ, Gardiner SM, et al. Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia. Nature 2000;405:797-800.
142. Longmore J, Hill RG, Hargreaves RJ. Neurokinin-receptor antagonists: pharmacological tools and therapeutic drugs. Can J Physiol Pharmacol 1997;75:612-621.
143. Page NM, Woods RJ, Lowry PJ. A regulatory role for neurokinin B in placental physiology and pre-eclampsia. Regul Pept 2001;98:97-104.
144. Burrows TD, King A, Loke YW. Expression of adhesion molecules by endovascular trophoblast and decidual endothelial cells: implications for vascular invasion during implantation. Placenta 1994;15:21-33.
145. Phocas I, Rizos D, Papoulias J, et al. A comparative study of serum soluble vascular cell adhesion molecule-1 and soluble intercellular adhesion molecule-1 in preeclampsia. J Perinatol 2000;20:114-119.
146. Djurovic S, Schjetlein R, Wisloff F, et al. Increased levels of intercellular adhesion molecules and vascular cell adhesion molecules in pre-eclampsia. Br J Obstet Gynaecol 1997;104:466-470.
147. Airoldi L, Gaffuri B, Rossi G, et al. Soluble intercellular adhesion molecule-1 serum profile in physiologic and preeclamptic pregnancy. Am J Reprod Immunol 1998;39:183-188.
148. Holzgreve W, Hahn S. Novel molecular biological approaches for the diagnosis of preeclampsia. Clin Chem 1999;45:451-452.
149. Holzgreve W, Li JJ, Steinborn A, et al. Elevation in erythroblast count in maternal blood before the onset of preeclampsia. Am J Obstet Gynecol 2001;184:165-168.
150. Zhong XY, Laivuori H, Livingston JC, et al. Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia. Am J Obstet Gynecol 2001;184:414-419.
151. Zhong XY, Holzgreve W, Hahn S. The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens Pregnancy 2002;21:77-83.
152. Leung TN, Zhang J, Lau TK, et al. Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin Chem 2001;47:137-139.
153. Zhong XY, Holzgreve W, Hahn S. Cell-free fetal DNA in the maternal circulation does not stem from the transplacental passage of fetal erythroblasts. Mol Hum Reprod 2002;8:864-870.
154. Soderstrom-Anttila V, Tiitinen A, Foudila T, et al. Obstetric and perinatal outcome after oocyte donation: comparison with in-vitro fertilization pregnancies. Hum Reprod 1998;13:483-490.
155. Sheffer-Mimouni G, Mashiach S, Dor J, et al. Factors influencing the obstetric and perinatal outcome after oocyte donation. Hum Reprod 2002;17:2636-2640.
156. Salha O, Sharma V, Dada T, et al. The influence of donated gametes on the incidence of hypertensive disorders of pregnancy. Hum Reprod 1999;14:2268-2273.
157. Lie RT, Rasmussen S, Brunborg H, et al. Fetal and maternal contributions to risk of pre-eclampsia: population based study. BMJ 1998;316:1343-1347.
158. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 1998;179:1359-1375.
159. Cincotta RB, Brennecke SP. Family history of pre-eclampsia as a predictor for pre-eclampsia in primigravidas. Int J Gynaecol Obstet 1998;60:23-27.
160. Arngrimsson R, Geirsson RT, Cooke A, et al. Renin gene restriction fragment length polymorphisms do not show linkage with preeclampsia and eclampsia. Acta Obstet Gynecol Scand 1994;73:10-13.
161. Moses EK, Lade JA, Guo G, et al. A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2. Am J Hum Genet 2000;67:1581-1585.
162. Harrison GA, Humphrey KE, Jones N, et al. A genomewide linkage study of preeclampsia/eclampsia reveals evidence for a candidate region on 4q. Am J Hum Genet 1997;60:1158-1167.
163. Livingston JC, Barton JR, Park V, et al. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol 2001;153-157.
164. Kim YJ, Williamson RA, Murray JC, et al. Genetic susceptibility to preeclampsia: roles of cytosine-to-thymine substitution at nucleotide 677 of the gene for methylenetetrahydrofolate reductase, 68-base pair insertion at nucleotide 844 of the gene for cystathionine beta-synthase, and factor V Leiden mutation.
165. Kahn SR. Severe preeclampsia associated with coinheritance of factor V Leiden mutation and protein S deficiency. Obstet Gynecol 1998;91:812-814.
166. Yoshimura T, Yoshimura M, Tabata A, et al. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with severe preeclampsia. J Soc Gynecol Investig 2000;7:238-241.
167. Arngrimsson R, Hayward C, Nadaud S, et al. Evidence for a familial pregnancy-induced hypertension locus in the eNOS-gene region. Am J Hum Genet 1997;61AB:354-362.
168. Bashford MT, Hefler LA, Vertrees TW, et al. Angiotensinogen and endothelial nitric oxide synthase gene polymorphisms among Hispanic patients with preeclampsia. Am J Obstet Gynecol 2001;184:1345-1350.
169. Savvidou MD, Vallance PJ, Nicolaides KH, et al. Endothelial nitric oxide synthase gene polymorphism and maternal vascular adaptation to pregnancy. Hypertension 2001;38:1289-1293.
170. Ward K, Hata A, Jeunemaitre X, et al. A molecular variant of angiotensinogen associated with preeclampsia. Nat Genet 1993;4:59-61.
171. Arngrimsson R, Purandare S, Connor M, et al. Angiotensinogen: a candidate gene involved in preeclampsia? Nat Genet 1993;4:114-115.
172. Sohda S, Arinami T, Hamada H, et al. Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. Am J Med Genet 1997;34:525-526.
173. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost 1997;77:1052-1054.
174. Zusterzeel PL, Peters WH, Visser W, et al. A polymorphism in the gene for microsomal epoxide hydrolase is associated with pre-eclampsia. Am J Med Genet 2001;38:234-237.
175. Chen G, Wilson R, Wang SH et al. Tumour necrosis factor-alpha (TNF-alpha) gene polymorphism and expression in pre-eclampsia. Clin Exp Immunol 1996;104:154-159.
176. Heiskanen J, Romppanen EL, Hiltunen M, et al. Polymorphism in the tumor necrosis factor-alpha gene in women with preeclampsia. J Assist Reprod Genet 2002;19:220-223.
177. FitzGerald DE, Drumm JE. Non-invasive measurement of human fetal circulation using ultrasound: a new method. BMJ 1977;2:1450-1451.
178. Thaler I, Manor D, Itskovitz J, et al. Changes in uterine blood flow during human pregnancy. Am J Obstet Gynecol 1990;162:121-125.
179. Bewley S, Campbell S, Cooper D. Uteroplacental Doppler flow velocity waveforms in the second trimester. A complex circulation. Br J Obstet Gynaecol 1989;96:1040-1046.
180. Schulman H, Fleischer A, Farmakides G, et al. Development of uterine artery compliance in pregnancy as detected by Doppler ultrasound. Am J Obstet Gynecol 1986;155:1031-1036.
181. Pearce JM, Campbell S, Cohen-Overbeek T, et al. References ranges and sources of variation for indices of pulsed Doppler flow velocity waveforms from the uteroplacental and fetal circulation. Br J Obstet Gynaecol 1988;95:248-256.
182. Brosens I, Robertson WB, Dixon HG. The physiological response of the vessels of the placental bed to normal pregnancy. J Pathol Bacteriol 1967;93:569-579.
183. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988;158:892-898.
184. Pijnenborg R, Bland JM, Robertson WB, et al. Uteroplacental arterial changes related to interstitial trophoblast migration in early human pregnancy. Placenta 1983;4:397-413.
185. Campbell S, Diaz-Recasens J, Griffin DR, et al. New Doppler technique for assessing uteroplacental blood flow. Lancet 1983;1:675-677.
186. McParland P, Pearce JM. Doppler blood flow in pregnancy. Placenta 1988;9:427-450.
187. Aardema MW, Oosterhof H, Timmer A, et al. Uterine artery Doppler flow and uteroplacental vascular pathology in normal pregnancies and pregnancies complicated by preeclampsia and small for gestational age fetuses. Placenta 2001;22:405-411.
188. Bower S, Bewley S, Campbell S. Improved prediction of preeclampsia by two-stage screening of uterine arteries using the early diastolic notch and color Doppler imaging. Obstet Gynecol 1993;82:78-83.
189. Bower SJ, Harrington KF, Schuchter K, et al. Prediction of pre-eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. Br J Obstet Gynaecol 1996;103:625-629.
190. Chan FY, Pun TC, Lam C, et al. Pregnancy screening by uterine artery Doppler velocimetry-which criterion performs best? Obstet Gynecol 1995;85:596-602.
191. Soutif C, Prevost A, Andre M. [Value of the systematic uterine Doppler in the primiparous woman. A series of 315 cases.] J Gynecol Obstet Biol Reprod (Paris) 1996;25:819-823.
192. Zimmermann P, Eirio V, Koskinen J, et al. Doppler assessment of the uterine and uteroplacental circulation in the second trimester in pregnancies at high risk for preeclampsia and/or intrauterine growth retardation: comparison and correlation between different Doppler parameters. Ultrasound Obstet Gynecol 1997;9:330-338.
193. Kurdi W, Campbell S, Aquilina J, et al. The role of color Doppler imaging of the uterine arteries at 20 weeks' gestation in stratifying antenatal care. Ultrasound Obstet Gynecol 1998;12:339-345.
194. Harrington K, Cooper D, Lees C, et al. Doppler ultrasound of the uterine arteries: the importance of bilateral notching in the prediction of pre-eclampsia, placental abruption or delivery of a small-for-gestational-age baby. Ultrasound Obstet Gynecol 1996;7:182-188.
195. Harrington K, Goldfrad C, Carpenter RG, et al. Transvaginal uterine and umbilical artery Doppler examination of 12-16 weeks and the subsequent development of pre-eclampsia and intrauterine growth retardation. Ultrasound Obstet Gynecol 1997;9:94-100.
196. Harrington K, Kurdi W, Aquilina J, et al. A prospective management study of slow-release aspirin in the palliation of uteroplacental insufficiency predicted by uterine artery Doppler at 20 weeks. Ultrasound Obstet Gynecol 2000;15:13-18.
197. Talbert DG. Uterine flow velocity waveform shape as an indicator of maternal and placental development failure mechanisms: a model-based synthesizing approach. Ultrasound Obstet Gynecol 1995;6:261-271.
198. Chien PF, Arnott N, Gordon A, et al. How useful is uterine artery Doppler flow velocimetry in the prediction of preeclampsia, intrauterine growth retardation and perinatal death? An overview. BJOG 2000;107:196-208.
199. Campbell S, Pearce JM, Hackett G, et al. Qualitative assessment of uteroplacental blood flow: early screening test for high-risk pregnancies. Obstet Gynecol 1986;68:649-653.
200. Arduini D, Rizzo G, Romanini C, et al. Utero-placental blood flow velocity waveforms as predictors of pregnancy-induced hypertension. Eur J Obstet Gynecol Reprod Biol 1987;26:335-341.
201. Hanretty KP, Primrose MH, Neilson JP, et al. Pregnancy screening by Doppler uteroplacental and umbilical artery waveforms. Br J Obstet Gynaecol 1989;96:1163-1167.
202. Steel SA, Pearce JM, McParland P, et al. Early Doppler ultrasound screening in prediction of hypertensive disorders of pregnancy. Lancet 1990;335:1548-1551.
203. Jacobson SL, Imhof R, Manning N, et al. The value of Doppler assessment of the uteroplacental circulation in predicting preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol 1990;162:110-114.
204. Harrington KF, Campbell S, Bewley S, et al. Doppler velocimetry studies of the uterine artery in the early prediction of pre-eclampsia and intra-uterine growth retardation. Eur J Obstet Gynecol Reprod Biol 1991;42(suppl):S14-S20.
205. Bewley S, Cooper D, Campbell S. Doppler investigation of uteroplacental blood flow resistance in the second trimester: a screening study for pre-eclampsia and intrauterine growth retardation. Br J Obstet Gynaecol 1991;98:871-879.
206. North RA, Ferrier C, Long D, et al. Uterine artery Doppler flow velocity waveforms in the second trimester for the prediction of preeclampsia and fetal growth retardation. Obstet Gynecol 1994;83:378-386.
207. Frusca T, Soregaroli M, Valcamonico A, et al. Doppler velocimetry of the uterine arteries in nulliparous women. Early Hum Dev 1997;48:177-185.
208. Mires GJ, Williams FL, Leslie J, et al. Assessment of uterine arterial notching as a screening test for adverse pregnancy outcome. Am J Obstet Gynecol 1998;179:1317-1323.
209. Martin AM, Bindra R, Curcio P, et al. Screening for preeclampsia and fetal growth restriction by uterine artery Doppler at 11-14 weeks of gestation. Ultrasound Obstet Gynecol 2001;18:583-586.
210. Papageorghiou AT, Yu CK, Bindra R, et al. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 2001;18:441-449.
211. Aquilina J, Thompson O, Thilaganathan B, et al. Improved early prediction of pre-eclampsia by combining second-trimester maternal serum inhibin-A and uterine artery Doppler. Ultrasound Obstet Gynecol 2001;17:477-484.
212. Becker R, Vonk R, Vollert W, et al. Doppler sonography of uterine arteries at 20-23 weeks: risk assessment of adverse pregnancy outcome by quantification of impedance and notch. J Perinat Med 2002;30:388-394.
213. Kayisli UA, Selam B, Demir R, et al. Expression of vasodilator-stimulated phosphoprotein in human placenta: possible implications in trophoblast invasion. Mol Hum Reprod 2002;8:88-94.
214. Georgiades P, Watkins M, Burton GJ, et al. Roles for genomic imprinting and the zygotic genome in placental development. Proc Natl Acad Sci U S A 2001;98:4522-4527.
215. Goffinet F, Aboulker D, Paris-Llado J, et al. Screening with a uterine Doppler in low risk pregnant women followed by low dose aspirin in women with abnormal results: a multicenter randomised controlled trial. BJOG 2001;108:510-518.